Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IHIVARNA

Financiado

Cerrado

Therapeutic TriMix mRNA based Vaccine in Chronic HIV 1 Infected Patients Recei...

Therapeutic TriMix mRNA based Vaccine in Chronic HIV 1 Infected Patients Receiving Antiretroviral Therapy To find a therapy alternative to cART for life is one of the hot topics of investigation in HIV field. Therapeutic vaccination seems to be the best option. We have reported in a double-blind placebo controlled study some of the be... ver más

30/11/2017

CONSORCI INSTITUT...

8M€

Presupuesto del proyecto: 8M€

Líder del proyecto

CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUE... Otra investigación y desarrollo experimental en ciencias naturales y técnicas organismos publicos

TRL 4-5 | 50K€

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-11-30 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

CONSORCI INSTITUT D INVESTIG...

0.00€ | Lider

SYNAPSE

N.D. | Participante

ITM

N.D. | Participante

FUNDACIO PRIVADA INSTITUT DE...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RNAmpMax Maximization of amplification of next generation RNA replico... 183K€ Cerrado

SAF2015-66193-R UTILIZACION DE MEDICINA DE SISTEMAS PARA LA PREDICCION DE LA... 182K€ Cerrado

SAF2013-45232-R VACUNAS FRENTE A ENFERMEDADES HUMANAS PREVALENTES Y OPTIMIZA... 593K€ Cerrado

EAVI2020 European AIDS Vaccine Initiative 2020 24M€ Cerrado

EHVA European HIV Vaccine Alliance EHVA a EU platform for the... 28M€ Cerrado

IMEIV Effect of insulin and feed/fast cycle on vaccine efficacy an... 176K€ Cerrado

Líder del proyecto

CONSORCI INSTITUT D INVESTIGACIONS BIOMEDIQUE... Otra investigación y desarrollo experimental en ciencias naturales y técnicas organismos publicos

TRL 4-5 | 50K€

Presupuesto del proyecto 8M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto To find a therapy alternative to cART for life is one of the hot topics of investigation in HIV field. Therapeutic vaccination seems to be the best option. We have reported in a double-blind placebo controlled study some of the best, most solid data showing that HIV-1 specific immune responses elicited by therapeutic dendritic cell (DC) vaccines pulsed ex vivo with inactivated autologous whole virus could significantly change pVL set-point (mean peak drop of -1.2 log10 copies/ml). Similar efficacy has been found in a preliminary non controlled clinical trial using DC electroporated with mRNA encoding autologous HIV-1 antigens. However, the logistics of developing a specific vaccine by ex vivo manipulating autologous DC for each patient may be prohibitive. Therefore, we propose that in vivo targeting of DC by direct administration of a rational designed HIV mRNA encoding immunomodulating proteins might be an attractive alternative to target DCs in situ. Our candidate is highly innovative: 1. It is a mRNA based immunogen: it is expected to have a good safety profile, it is classified as nongene therapy by the American and German authorities, is easier to produce and to store regardless of the encoded antigen and is not restricted to a defined HLA type of individuals. 2. The HIV antigen encoded by mRNA has been selected with a rational design: based on our previous works selecting viral targets of protective HIV-1 specific T cell responses in 3 large cohorts of HIV infected individuals. 3. The candidate includes TriMix to target DC in vivo: our data suggest that mRNA encoding a mixture of antigen presenting cells activation molecules (CD40L, a constitutive active variant of TLR4 and CD70) significantly enhanced the induction of antigen-specific T cells. If this candidate would be able to obtain the functional cure in at least a proportion of patients it could be applicable to developing countries and would improve the care and cost of HIV infection.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores